P.CEZANNE - Ended PDF Print E-mail

Integration of Nano-Biology and ICT to Provide a Continuous Care and Implantable Monitoring System for Diabetic patients






Project Budget 14,143,000 Euros

The main objectives are to research and develop a novel implantable long-term nano-sensor for continuous BGL monitoring. The nano-sensor will be linked to the wireless device platform of the ICT system and the data will be automatically collected, stored and processed. The novelty of P.CÉZANNE lies within the nano-sensor containing living cells or proteins, compact capsule with optics and microelectronics that measures continuously and provides physicians with real-time online medical data.

The system design may be applicable to other diseases related to monitoring other medical parameters by changing the biological substrate in the sensor. Such technology will provide better means for monitoring and treating people with diabetes.

Strategic Objectives

Diabetes is one of the most common chronic diseases in human and therefore one of the main strategic directions of diagnostic research is aimed towards diabetes care. The major concern in diabetes care is to monitor and stabilise BGL (blood glucose level) while allowing the patient a normal routine life.

With this goal in mind, the P.CÉZANNE project proposes to integrate and to apply a real-time convergence between nano-biology and nano-chemistry; silicon and non silicon technologies; micro-optics and microelectronics and ICT, by implementing it into a novel minimum invasive and long term implantable glucose sensing and treating micro device.

The newly developed system could provide the capability for automatic regulation of the glucose level by linking it to an insulin pump that accurately releases insulin into the body in response to the fluctuations of glucose concentrations. Furthermore, the system design could be applicable to other diseases related to monitoring other medical parameters by changing the biological substrate in the sensor.

Hence the project’s strategic objectives are:

  • Research and development of an innovative nano-biotechnological sensor for continuous BGL monitoring system for diabetic patients.
  • Development of an ICT Platform with RF transceivers linking the continuous BGL sensors and the optional insulin infusion units to a central monitoring service system.
  • Integration and validation (both in vitro and in-vivo) of the complete prototype system

The Consortium

Participant name


Clalit Health Services, Meir Hospital, Kfar Saba


Polymer Institute of the Slovak Academy of Sciences Research


Foundation of Research and Technology Hellas


Centro Nacional de Micro-electrónica.


Fraunhofer Institute


Philips – FIMI S.r.l.


Labman Automation Ltd.


Robert Bosch GmbH


ProTech AF Limited


Siveco Romania SA


MicroTech S.r.l.


O.S.M-DAN Ltd.


Afcon Industries Ltd


Tadiran Batteries Ltd.


Bar Ilan University